Why the study?
Decisions on optimal dual or triple antithrombotic therapy in patients with multiple clinical risk factors after PCI are challenging and not supported by clear guideline recommendations.
What is the incidence of bleeding and ischaemic events in high-risk patients on dual/triple antithrombotic therapy after PCI?
What is the incidence of bleeding and ischaemic events in high-risk patients on dual/triple antithrombotic therapy after PCI?
High-risk patients with multiple clinical risk factors on dual/triple antithrombotic therapy after PCI experience high rates of both bleeding (48.5%) and ischemic events (13.2%) at 6-12 months.
Answers are grounded in this paper and cite their sources.
High event rates support individualized antithrombotic strategies in high-risk post-PCI patients; leaves open optimal regimen selection.
BACKGROUND: Patients with multiple clinical risk factors are a complex group in whom both bleeding and recurrent ischaemic events often occur during treatment with dual/triple antithrombotic therapy after percutaneous coronary intervention. Decisions on optimal antithrombotic treatment in these patients are challenging and not supported by clear guideline recommendations. A prospective observational cohort study was set up to evaluate patient-related factors, platelet reactivity, genetics, and a broad spectrum of biomarkers in predicting adverse events in these high-risk patients. Aim of the current paper is to present the study design, with a detailed description of the cohort as a whole, and evaluation of bleeding and ischaemic outcomes during follow-up, thereby facilitating future research questions focusing on specific data provided by the cohort. METHODS: We included patients with ≥ 3 predefined risk factors who were treated with dual/triple antithrombotic therapy following PCI. We performed a wide range of haemostatic tests and collected all ischaemic and bleeding events during 6-12 months follow-up. RESULTS: We included 524 high-risk patients who underwent PCI within the previous 1-2 months. All patients used a P2Y12 inhibitor (clopidogrel n = 388, prasugrel n = 61, ticagrelor n = 75) in combination with aspirin (n = 397) and/or anticoagulants (n = 160). Bleeding events were reported by 254 patients (48.5%), necessitating intervention or hospital admission in 92 patients (17.5%). Major adverse cardiovascular events (myocardial infarction, stroke, death) occurred in 69 patients (13.2%). CONCLUSION: The high risk for both bleeding and ischaemic events in this cohort of patients with multiple clinical risk factors illustrates the challenges that the cardiologist faces to make a balanced decision on the optimal treatment strategy. This cohort will serve to answer several future research questions about the optimal management of these patients on dual/triple antithrombotic therapy, and the possible value of a wide range of laboratory tests to guide these decisions.
No takes yet. Share an insight, caveat, or question.
Olie et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: